← back to search

Douglas C. Palmer

AstraZeneca (Japan) · JP
Area of research
Immunology · Oncology
Research interest
Research interests include CAR-T cell therapy research, Immune Cell Function and Interaction, Immunotherapy and Immune Responses, and Cancer Immunotherapy and Biomarkers.
h-index
51
citations
17,562
works
199
NIH funding
primary concept
Biology
email

Recent publications

Initial TCR Signal Strength Imprints GATA3 and Tbet Expression Driving T-helper Cell Fate Decisions
2024cited by 2position: contributordoi
Data from Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest
2023cited by 0position: middledoi
A T cell resilience model associated with response to immunotherapy in multiple tumor types
Nature Medicine 2022cited by 62position: middledoi
A T cell resilience model associated with response to immunotherapy in multiple tumor types.
2022cited by 53position: contributordoi
STING agonist promotes CAR T cell trafficking and persistence in breast cancer
Journal of Experimental Medicine 2020cited by 164position: contributordoi
Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies.
2020cited by 130position: contributordoi
Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade
2020cited by 1position: contributordoi
T cell stemness and dysfunction in tumors are triggered by a common mechanism
Science 2019cited by 525position: middledoi
T cell stemness and dysfunction in tumors are triggered by a common mechanism.
2019cited by 429position: contributordoi
Genome-wide profiling of druggable active tumor defense mechanisms to enhance cancer immunotherapy
2019cited by 0position: contributordoi
Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche
Cell 2016cited by 240position: middledoi
Lineage relationship of CD8+ T cell subsets is revealed by progressive changes in the epigenetic landscape
Cellular and Molecular Immunology 2015cited by 120position: middledoi
Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest
Cancer Immunology Research 2014cited by 27position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Christopher A. Klebanoff · Memorial Sloan Kettering Cancer Center3 papers (2015–2019)Nicholas P. Restifo · Business Roundtable3 papers (2015–2019)Madhusudhanan Sukumar · Johnson & Johnson (United States)3 papers (2015–2019) · 3 papers (2019–2024)Rahul Roychoudhuri · Center for Cancer Research3 papers (2015–2019)Nicholas P. Restifo · Johns Hopkins University2 papers (2019–2020)Shashank J. Patel · Indian Agricultural Research Institute2 papers (2015–2019)Rigel J. Kishton · National Cancer Institute2 papers (2019–2022)Zhiya Yu · National Cancer Institute2 papers (2016–2019)Luca Gattinoni · University of Regensburg2 papers (2015–2016)Robert Eil · University of Portland2 papers (2016–2019)Xin‐Yuan Guan · Chongqing Jiaotong University2 papers (2022–2022)Kenneth Aldape · National Institute of Mental Health2 papers (2022–2022)Anthony T. Phan · California University of Pennsylvania1 papers (2016–2016)Weiqun Peng · University of Kansas1 papers (2015–2015)Manikandan Narayanan · National Institute of Allergy and Infectious Diseases1 papers (2015–2015)Joseph G. Crompton · Sarcoma Oncology Center1 papers (2015–2015)Xiaojing Liu · North Carolina State University1 papers (2019–2019)Yu Zhang · Guangzhou University of Chinese Medicine1 papers (2022–2022)Thanh Nguyen · Hospital for Sick Children1 papers (2022–2022)